Ciclosporin

Last updated

Ciclosporin
Ciclosporin.svg
Ciclosporin-A-from-xtal-3D-bs-17.png
Clinical data
Pronunciation /ˌsaɪkləˈspɔːrɪn/ [1]
Trade names Sandimmune, others
Other namescyclosporin, ciclosporin A, [2] cyclosporine A, cyclosporin A (CsA), cyclosporine (USAN US)
AHFS/Drugs.com Monograph
MedlinePlus a601207
License data
Pregnancy
category
  • AU:C
Routes of
administration 		Oral, intravenous (IV), eye drops
Drug class Calcineurin inhibitor
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability variable
Metabolism Liver CYP3A4
Elimination half-life variable (about 24 hours)
Excretion Bile duct
Identifiers
  • (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.119.569 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C62H111N11O12
Molar mass 1202.635 g·mol−1
3D model (JSmol)
  • CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
  • InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1 Yes check.svgY
  • Key:PMATZTZNYRCHOR-CGLBZJNRSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Ciclosporin, also spelled cyclosporine and cyclosporin, is a calcineurin inhibitor, used as an immunosuppressant medication. It is taken orally or intravenously for rheumatoid arthritis, psoriasis, Crohn's disease, nephrotic syndrome, eczema, and in organ transplants to prevent rejection. [14] [15] It is also used as eye drops for keratoconjunctivitis sicca (dry eyes). [16]

Contents

Common side effects include high blood pressure, headache, kidney problems, increased hair growth, and vomiting. [15] Other severe side effects include an increased risk of infection, liver problems, and an increased risk of lymphoma. [15] Blood levels of the medication should be checked to decrease the risk of side effects. [15] Use during pregnancy may result in preterm birth; however, ciclosporin does not appear to cause birth defects. [17]

Ciclosporin is believed to work by decreasing the function of lymphocytes. [15] It does this by forming a complex with cyclophilin to block the phosphatase activity of calcineurin, which in turn decreases the production of inflammatory cytokines by T-lymphocytes. [18]

Ciclosporin was isolated in 1971 from the fungus Tolypocladium inflatum and came into medical use in 1983. [19] It is on the World Health Organization's List of Essential Medicines. [20] [21] In 2022, it was the 185th most commonly prescribed medication in the United States, with more than 2 million prescriptions. [22] [23] It is available as a generic medication. [24]

Medical uses

Ciclosporin is indicated to treat and prevent graft-versus-host disease in bone marrow transplantation and to prevent rejection of kidney, heart, and liver transplants. [8] [7] It is also approved in the US for treating of rheumatoid arthritis and psoriasis, persistent nummular keratitis following adenoviral keratoconjunctivitis, [25] [7] and as eye drops for treating dry eyes caused by Sjögren's syndrome and meibomian gland dysfunction. [9]

In addition to these indications, ciclosporin is also used in severe atopic dermatitis, [26] It has been used in severe rheumatoid arthritis and related diseases. [27]

Ciclosporin has also been used in people with acute severe ulcerative colitis and hives that do not respond to treatment with steroids. [28]

Side effects

Side effects of ciclosporin can include gum enlargement, increased hair growth, convulsions, peptic ulcers, pancreatitis, fever, vomiting, diarrhea, confusion, increased cholesterol, trouble breathing, numbness and tingling (particularly of the lips), itchiness, high blood pressure, potassium retention (possibly leading to hyperkalemia), kidney and liver dysfunction, [29] burning sensations at finger tips, and an increased vulnerability to opportunistic fungal and viral infections. Ciclosporin causes hypertension by inducing vasoconstriction in the kidneys and increasing sodium reabsorption. The increase in blood pressure can cause cardiovascular events; it is thus recommended that the lowest effective dose for people requiring long-term treatment be used. [30]

Ciclosporin use after a kidney transplantation is associated with increased levels of uric acid in the blood and, in some cases, gout. [31]

Ciclosporin is listed as an IARC Group 1 carcinogen (i.e. there is sufficient evidence of carcinogenicity in humans), [32] specifically leading to squamous cell skin cancer and non-Hodgkin lymphoma. [33]

Pharmacology

Mechanism of action

Ciclosporin's main effect is to lower the activity of T-cells; it does so by inhibiting calcineurin in the calcineurin–phosphatase pathway and preventing the mitochondrial permeability transition pore from opening. Ciclosporin binds to the cytosolic protein cyclophilin (immunophilin) of lymphocytes, especially of T cells. This cyclosporin—cyclophilin complex inhibits calcineurin, which is normally responsible for activating the transcription of interleukin 2. In T-cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. Calcineurin then dephosphorylates the transcription factor NF-AT (nuclear factor of activated T-cells), which moves to the T-cell nucleus and increases the transcription of genes for IL-2 and related cytokines. [18] Ciclosporin, by preventing the dephosphorylation of NF-AT, leads to reduced effector T-cell function; [34] [35] [36] [37] it does not affect cytostatic activity.[ medical citation needed ]

Ciclosporin also binds to the cyclophilin D protein that constitutes part of the mitochondrial permeability transition pore (MPTP), [35] [38] thus preventing MPTP opening. The MPTP is found in the mitochondrial membrane of cardiac muscle cells. MPTP opening signifies a sudden change in the inner mitochondrial membrane permeability, allowing protons and other ions and solutes of a size up to ~1.5 kDa to go through the inner membrane. This change of permeability is considered a cellular catastrophe, [39] [40] leading to cell death. However, brief mitochondrial permeability transition pore openings play an essential physiological role in maintaining healthy mitochondrial homeostasis. [41]

Ciclosporin can induce a remission of proteinuria caused by such diseases as MCD and FSGS. [42] Ciclosporin blocks the calcineurin-mediated dephosphorylation of synaptopodin, a regulator of Rho GTPases in podocytes, thereby preserving the phosphorylation-dependent synaptopodin-14-3-3 beta interaction. Preservation of this interaction, in turn, protects synaptopodin from cathepsin L-mediated degradation. Altogether, the antiproteinuric effect of Ciclosporin results, at least in part, from the maintenance of synaptopodin protein abundance in podocytes, which, in turn, is sufficient to maintain the integrity of the glomerular filtration barrier and to safeguard against proteinuria. [43]

Pharmacokinetics

Ciclosporin is a cyclic peptide of 11 amino acids; it contains a single D-amino acid, which is rarely encountered in nature. Unlike most peptides, ciclosporin is not synthesized by ribosomes. [44]

Ciclosporin is highly metabolized in humans and animals after ingestion. The metabolites, which include cyclosporin B, C, D, E, H, and L, [45] have less than 10% of ciclosporin's immunosuppressant activity and are associated with higher kidney toxicity. [46]

Biosynthesis

Cyclosporin biosynthesis. Bmt = butenyl-methyl-threonine, Abu = L-alpha-aminobutyric acid, Sar = sarcosine BScyclosporin2.png
Cyclosporin biosynthesis. Bmt = butenyl-methyl-threonine, Abu = L-alpha-aminobutyric acid, Sar = sarcosine

Cyclosporin is synthesized by a nonribosomal peptide synthetase, cyclosporin synthetase. [47] The enzyme contains an adenylation domain, a thiolation domain, a condensation domain, and an N-methyltransferase domain. The adenylation domain is responsible for substrate recognition and activation, whereas the thiolation domain covalently binds the adenylated amino acids to phosphopantetheine, and the condensation domain elongates the peptide chain. Cyclosporin synthetase substrates include L-valine, L-leucine, L-alanine, glycine, 2-aminobutyric acid, 4-methylthreonine, and D-alanine, which is the starting amino acid in the biosynthetic process. [48] With the adenylation domain, cyclosporin synthetase generates the acyl-adenylated amino acids, then covalently binds the amino acid to phosphopantetheine through a thioester linkage. Some of the amino acid substrates become N-methylated by S-adenosyl methionine. The cyclization step releases cyclosporin from the enzyme. [49] Amino acids such as D-Ala and butenyl-methyl-L-threonine (Bmt) indicate cyclosporin synthetase requires the action of other enzymes. The racemization of L-Ala to D-Ala by alanine racemase is pyridoxal phosphate-dependent. The formation of butenyl-methyl-L-threonine is performed by a Bmt polyketide synthase that uses acetate/malonate as its starting material. [50]

Gene cluster

Tolypocladium inflatum, the species currently used for mass production of Cyclosporin, has the biosynthetic genes arranged into a 12-gene cluster. Of these 12 genes, SimA ( Q09164 ) is the cyclosporin synthetase, SimB ( CAA02484.1 ) is the alanine racemase, and SimG (similar to ATQ39432.1 ) is the polyketide synthase. [51] These genes are associated with an active retrotransposon. [52] Although these sequences are poorly-annotated on GenBank and other databases, 90% similar sequences can be found for the Cyclosporin-producing Beauveria felina (or Amphichorda ~). [53] SimB has two paralogs in the same organism with different but overlapping functions thanks to their low specificity. [54]

History

In 1970, new strains of fungi were isolated from soil samples taken from Norway and from Wisconsin in the US by employees of Sandoz (now Novartis) in Basel, Switzerland. Both strains produced a family of natural products called cyclosporins. Two related components that had antifungal activity were isolated from extracts from these fungi. The Norwegian strain, Tolypocladium inflatum Gams , was later used for the large scale fermentation of ciclosporin. [55]

The immunosuppressive effect of the natural product ciclosporin was discovered on 31 January 1972 [56] in a screening test on immune suppression designed and implemented by Hartmann F. Stähelin at Sandoz. [57] [55] The chemical structure of cyclosporin was determined in 1976, also at Sandoz. [58] [59] The success of the drug candidate ciclosporin in preventing organ rejection was shown in kidney transplants by R.Y. Calne and colleagues at the University of Cambridge, [60] and in liver transplants performed by Thomas Starzl at the Children's Hospital of Pittsburgh. The first patient, on 9 March 1980, was a 28-year-old woman. [61] In the United States, the Food and Drug Administration (FDA) approved ciclosporin for clinical use in 1983. [62] [63] [64] [65]

Thomas Starzl's 1992 memoir explains through the eyes of a transplant surgeon that ciclosporin was an epoch-making drug for solid organ allotransplantation. [66] It greatly expanded the clinical applicability of such transplantation by substantially advancing the antirejection pharmacotherapy component. [66] Put simply, the biggest limits of applying such transplantation more widely were not cost or surgical skill (as formidable as those are) but rather the problem of allograft rejection and the scarcity of donor organs. Ciclopsporin was a major advancement against the rejection part of the challenge. [66]

Society and culture

In July 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vevizye, intended for the treatment of dry eye disease. [12] The applicant for this medicinal product is Novaliq GmbH. [12] Vevizye was authorized for medical use in the European Union in September 2024. [12]

Names

The natural product was named cyclosporin by the German-speaking scientists who first isolated it [55] and cyclosporine when translated into English. Per International Nonproprietary Name (INN) guidelines for drugs, [67] the y was replaced with i so that the INN for the medication is spelled ciclosporin.[ citation needed ]

Ciclosporin is the INN and the British Approved Name (BAN), while cyclosporine is the United States Adopted Name (USAN) and cyclosporin is a former BAN. [68]

Available forms

Ciclosporin exhibits very poor solubility in water, and, as a consequence, suspension and emulsion forms of the medication have been developed for oral administration and for injection. Ciclosporin was originally brought to market by Sandoz (now Novartis), under the brand name Sandimmune, which is available as soft gelatin capsules, an oral solution, and a formulation for intravenous administration. These are all nonaqueous compositions. [8] A newer microemulsion, [69] orally-administered formulation, Neoral, [7] is available as a solution and as soft gelatin capsules. Compositions of Neoral are designed to form microemulsions in contact with water. [70] [71]

Generic ciclosporin preparations have been marketed under various brand names, including Cicloral (by Sandoz/Hexal), Gengraf (by Abbott) and Deximune (by Dexcel Pharma). Since 2002, a topical emulsion of ciclosporin for treating inflammation caused by keratoconjunctivitis sicca (dry eye syndrome) has been marketed under the brand name Restasis. [9] Ikervis is a similar formulation with a concentration of 0.1%. [72] Inhaled ciclosporin formulations are in clinical development, and include a solution in propylene glycol and liposome dispersions. [73] [74]

Research

Neuroprotection

Ciclosporin is in a phase II/III (adaptive) clinical study in Europe to determine its ability to ameliorate neuronal cellular damage and reperfusion injury (phase III) in traumatic brain injury. This multi-center study is being organized by NeuroVive Pharma and the European Brain Injury Consortium using NeuroVive's formulation of ciclosporin called Neurostat (also known by its cardioprotection brand name of Ciclomulsion). This formulation uses a lipid emulsion base instead of cremophor and ethanol. [75] NeuroSTAT was compared to Sandimmune in a phase I study and found to be bioequivalent. In this study, NeuroSTAT did not exhibit the anaphylactic and hypersensitivity reactions found in cremophor- and ethanol-based products. [76]

Ciclosporin has been investigated as a possible neuroprotective agent in conditions such as traumatic brain injury, and has been shown in animal experiments to reduce brain damage associated with injury. [77] Ciclosporin blocks the formation of the mitochondrial permeability transition pore, which has been found to cause much of the damage associated with head injury and neurodegenerative diseases. Ciclosporin's neuroprotective properties were first discovered in the early 1990s when two researchers (Eskil Elmér and Hiroyuki Uchino) were conducting experiments in cell transplantation. An unintended finding was that cyclosporin A was strongly neuroprotective when it crossed the blood–brain barrier. [78] This same process of mitochondrial destruction through the opening of the MPT pore is implicated in making traumatic brain injuries much worse. [79]

Cardiac disease

Ciclosporin has been used experimentally to treat cardiac hypertrophy [35] [80] (an increase in cell volume).

Inappropriate opening of the mitochondrial permeability transition pore (MPTP) manifests in ischemia [35] (blood flow restriction to tissue) and reperfusion injury [35] (damage occurring after ischemia when blood flow returns to tissue), after myocardial infarction [36] (heart attack) and when mutations in mitochondrial DNA polymerase occur. [35] The heart attempts to compensate for disease state by increasing the intracellular Ca2+
 to increase the contractility cycling rates. [38] Constitutively high levels of mitochondrial Ca2+
 cause inappropriate MPTP opening leading to a decrease in the cardiac range of function, leading to cardiac hypertrophy as an attempt to compensate for the problem. [38] [36]

Cyclosporin A has been shown to decrease cardiac hypertrophy by affecting cardiac myocytes in many ways. Cyclosporin A binds to cyclophilin D to block the opening of MPTP, and thus decreases the release of protein cytochrome C, which can cause programmed cell death. [35] [38] [81] CypD is a protein within the MPTP that acts as a gate; binding by cyclosporin A decreases the amount of inappropriate opening of MPTP, which decreases the intramitochondrial Ca2+
. [38] Decreasing intramitochondrial Ca2+
 allows for reversal of cardiac hypertrophy caused in the original cardiac response. [38] Decreasing the release of cytochrome C caused decreased cell death during injury and disease. [35] Cyclosporin A also inhibits the phosphatase calcineurin pathway (14). [35] [36] [82] Inhibition of this pathway has been shown to decrease myocardial hypertrophy. [36] [80] [82]

Veterinary use

The medication is approved in the United States for the treatment of atopic dermatitis in dogs. [83] Unlike the human form of the medication, the lower doses used in dogs mean the drug acts as an immunomodulator and has fewer side effects than in humans. The benefits of using this product include the reduced need for concurrent therapies to bring the condition under control. It is available as an ophthalmic ointment for dogs called Optimmune, manufactured by Intervet, which is part of Merck. It is also used to treat sebaceous adenitis (immune response against the sebaceous glands), pemphigus foliaceus (autoimmune blistering skin disease), Inflammatory bowel disease, anal furunculosis (anal inflammatory disease), and myasthenia gravis (a neuromuscular disease). [83] [84]

Related Research Articles

<span class="mw-page-title-main">Tacrolimus</span> Immunosuppressive drug

Tacrolimus, sold under the brand name Prograf among others, is an immunosuppressive drug. After allogenic organ transplant, the risk of organ rejection is moderate. To lower the risk of organ rejection, tacrolimus is given. The drug can also be sold as a topical medication in the treatment of T cell-mediated diseases such as eczema and psoriasis. For example, it is prescribed for severe refractory uveitis after a bone marrow transplant, exacerbations of minimal change disease, Kimura's disease, and vitiligo. It can be used to treat dry eye syndrome in cats and dogs.

<span class="mw-page-title-main">Immunosuppressive drug</span> Drug that inhibits activity of immune system

Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications, are drugs that inhibit or prevent the activity of the immune system.

<span class="mw-page-title-main">Azathioprine</span> Immunosuppressive medication

Azathioprine, sold under the brand name Imuran, among others, is an immunosuppressive medication. It is used for the treatment of rheumatoid arthritis, granulomatosis with polyangiitis, Crohn's disease, ulcerative colitis, and systemic lupus erythematosus; and in kidney transplants to prevent rejection. It is listed by the International Agency for Research on Cancer as a group 1 human carcinogen. It is taken by mouth or injected into a vein.

<span class="mw-page-title-main">Sirolimus</span> Pharmaceutical drug

Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mammalian target of rapamycin (mTOR) kinase inhibitor that reduces the sensitivity of T cells and B cells to interleukin-2 (IL-2), inhibiting their activity.

<span class="mw-page-title-main">Graft-versus-host disease</span> Medical condition

Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. GvHD is commonly associated with bone marrow transplants and stem cell transplants.

<span class="mw-page-title-main">Reperfusion injury</span> Tissue damage after return of blood supply following ischemia or hypoxia

Reperfusion injury, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue after a period of ischemia or lack of oxygen. The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than restoration of normal function.

<span class="mw-page-title-main">Cyclophilin</span>

Cyclophilins (CYPs) are a family of proteins named after their ability to bind to ciclosporin, an immunosuppressant which is usually used to suppress rejection after internal organ transplants. They are found in all domains of life. These proteins have peptidyl prolyl isomerase activity, which catalyzes the isomerization of peptide bonds from trans form to cis form at proline residues and facilitates protein folding.

The mitochondrial permeability transition pore is a protein that is formed in the inner membrane of the mitochondria under certain pathological conditions such as traumatic brain injury and stroke. Opening allows increase in the permeability of the mitochondrial membranes to molecules of less than 1500 daltons in molecular weight. Induction of the permeability transition pore, mitochondrial membrane permeability transition, can lead to mitochondrial swelling and cell death through apoptosis or necrosis depending on the particular biological setting.

Tolypocladium inflatum is an ascomycete fungus originally isolated from a Norwegian soil sample that, under certain conditions, produces the immunosuppressant drug ciclosporin. In its sexual stage (teleomorph) it is a parasite on scarab beetles. It forms a small, compound ascocarp that arises from the cadaver of its host beetle. In its asexual stage (anamorph) it is a white mold that grows on soil. It is much more commonly found in its asexual stage and this is the stage that was originally given the name Tolypocladium inflatum.

<span class="mw-page-title-main">FKBP</span>

The FKBPs, or FK506 binding proteins, constitute a family of proteins that have prolyl isomerase activity and are related to the cyclophilins in function, though not in amino acid sequence. FKBPs have been identified in many eukaryotes, ranging from yeast to humans, and function as protein folding chaperones for proteins containing proline residues. Along with cyclophilin, FKBPs belong to the immunophilin family.

<span class="mw-page-title-main">NIM811</span> Chemical compound

NIM811 is a mitochondrial permeability transition inhibitor. Also known as N-methyl-4-isoleucine cyclosporin, it is a substituted cyclosporine analog that binds to cyclophilin; however, this binary complex cannot bind to calcineurin, and therefore lacks immunosuppressive activity.

Hartmann F. Stähelin was a Swiss pharmacologist with an outstanding record in basic and applied cancer and immunology research. He discovered two important drugs: etoposide and ciclosporin.

<span class="mw-page-title-main">PPIB</span> Protein-coding gene in the species Homo sapiens

Peptidyl-prolyl cis-trans isomerase B is an enzyme that is encoded by the PPIB gene. As a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family, this protein catalyzes the cis-trans isomerization of proline imidic peptide bonds, which allows it to regulate protein folding of type I collagen. Generally, PPIases are found in all eubacteria and eukaryotes, as well as in a few archaebacteria, and thus are highly conserved.

<span class="mw-page-title-main">Peptidylprolyl isomerase D</span> Protein-coding gene in the species Homo sapiens

Peptidylprolyl isomerase D (cyclophilin D), also known as PPID, is an enzyme which in humans is encoded by the PPID gene on chromosome 4. As a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family, this protein catalyzes the cis-trans isomerization of proline imidic peptide bonds, which allows it to facilitate folding or repair of proteins. In addition, PPID participates in many biological processes, including mitochondrial metabolism, apoptosis, redox, and inflammation, as well as in related diseases and conditions, such as ischemic reperfusion injury, AIDS, and cancer.

<span class="mw-page-title-main">Calcium modulating ligand</span> Protein-coding gene in humans

Calcium modulating ligand, also known as calcium-modulating cyclophilin ligand, is a signalling protein recognized by the TNF receptor TACI.

<span class="mw-page-title-main">PPIF</span> Protein-coding gene in the species Homo sapiens

Peptidyl-prolyl cis-trans isomerase, mitochondrial (PPIF) is an enzyme that in humans is encoded by the PPIF gene. It has also been referred to as, but should not be confused with, cyclophilin D (CypD), which is encoded by the PPID gene. As a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family, this protein catalyzes the cis-trans isomerization of proline imidic peptide bonds, which allows it to facilitate folding or repair of proteins. PPIF is a major component of the mitochondrial permeability transition pore (MPTP) and, thus, highly involved in mitochondrial metabolism and apoptosis, as well as in mitochondrial diseases and related conditions, including cardiac diseases, neurodegenerative diseases, and muscular dystrophy. In addition, PPIF participates in inflammation, as well as in ischemic reperfusion injury, AIDS, and cancer.

<span class="mw-page-title-main">PPIC</span> Protein-coding gene in the species Homo sapiens

Peptidyl-prolyl cis-trans isomerase C (PPIC) is an enzyme that in humans is encoded by the PPIC gene on chromosome 5. As a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family, this protein catalyzes the cis-trans isomerization of proline imidic peptide bonds, which allows it to facilitate folding or repair of proteins. In addition, PPIC participates in many biological processes, including mitochondrial metabolism, apoptosis, redox, and inflammation, as well as in related diseases and conditions, such as ischemic reperfusion injury, AIDS, and cancer.

Ciclosporin is a cyclic polypeptide that has been used widely as an orally-available immunosuppressant. It was originally used to prevent transplant rejection of solid organs but has also found use as an orally administered agent to treat psoriasis, rheumatoid arthritis, dry eye and other auto-immune related conditions. A variety of pre-clinical and clinical studies have been and are investigating its use to treat lung-related disorders via inhalation.

<span class="mw-page-title-main">Voclosporin</span> Medication

Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis. It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability.

Ischemia-reperfusion (IR) tissue injury is the resultant pathology from a combination of factors, including tissue hypoxia, followed by tissue damage associated with re-oxygenation. IR injury contributes to disease and mortality in a variety of pathologies, including myocardial infarction, ischemic stroke, acute kidney injury, trauma, circulatory arrest, sickle cell disease and sleep apnea. Whether resulting from traumatic vessel disruption, tourniquet application, or shock, the extremity is exposed to an enormous flux in vascular perfusion during a critical period of tissue repair and regeneration. The contribution of this ischemia and subsequent reperfusion on post-traumatic musculoskeletal tissues is unknown; however, it is likely that similar to cardiac and kidney tissue, IR significantly contributes to tissue fibrosis.

References

  1. ↑ "cyclosporin". Dictionary.com Unabridged. Random House. n.d. Archived from the original on 18 November 2010. Retrieved 13 July 2011.
  2. ↑ Laupacis A, Keown PA, Ulan RA, McKenzie N, Stiller CR (May 1982). "Cyclosporin A: a powerful immunosuppressant". Canadian Medical Association Journal. 126 (9): 1041–6. PMC   1863293 . PMID   7074504.
  3. ↑ "Regulatory Decision Summary for Restasis Multidose". Drug and Health Product Register. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
  4. ↑ "Regulatory Decision Summary for Verkazia". Drug and Health Product Register. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
  5. ↑ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada . 3 August 2022. Retrieved 25 March 2024.
  6. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  7. 1 2 3 4 "Neoral- cyclosporine capsule, liquid filled Neoral- cyclosporine solution". DailyMed. Archived from the original on 5 July 2013. Retrieved 3 February 2022.
  8. 1 2 3 "Sandimmune- cyclosporine capsule, liquid filled Sandimmune- cyclosporine injection Sandimmune- cyclosporine solution". DailyMed. Archived from the original on 21 April 2014. Retrieved 3 February 2022.
  9. 1 2 3 "Restasis- cyclosporine emulsion". DailyMed. Archived from the original on 30 March 2014. Retrieved 3 February 2022.
  10. ↑ "Vevye- cyclosporine ophthalmic solution solution/ drops". DailyMed. 26 May 2023. Archived from the original on 29 August 2023. Retrieved 29 August 2023.
  11. ↑ "Ikervis". European Medicines Agency. 17 September 2018. Archived from the original on 13 August 2022. Retrieved 27 February 2023.
  12. 1 2 3 4 "Vevizye EPAR". European Medicines Agency. 25 July 2024. Retrieved 27 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  13. ↑ "Vevizye PI". Union Register of medicinal products. 23 September 2024. Retrieved 27 September 2024.
  14. ↑ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 221. hdl: 10665/44053 . ISBN   9789241547659.
  15. 1 2 3 4 5 "Cyclosporine". The American Society of Health-System Pharmacists. Archived from the original on 17 October 2016. Retrieved 8 December 2016.
  16. ↑ "Cyclosporine eent". The American Society of Health-System Pharmacists. Archived from the original on 13 January 2016. Retrieved 8 December 2016.
  17. ↑ "Cyclosporine Use During Pregnancy". Drugs.com. Archived from the original on 14 September 2017. Retrieved 20 December 2016.
  18. 1 2 Matsuda S, Koyasu S (May 2000). "Mechanisms of action of cyclosporine" (PDF). Immunopharmacology. 47 (2–3): 119–25. doi:10.1016/S0162-3109(00)00192-2. PMID   10878286. Archived from the original (PDF) on 11 August 2017. Retrieved 4 March 2018.
  19. ↑ Watts R, Clunie G, Hall F, Marshall T (2009). Rheumatology. Oxford University Press. p. 558. ISBN   978-0-19-922999-4. Archived from the original on 5 November 2017.
  20. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  21. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  22. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  23. ↑ "Cyclosporine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  24. ↑ "FDA Approves First Generic of Restasis". U.S. Food and Drug Administration (FDA) (Press release). 2 February 2022. Archived from the original on 2 February 2022. Retrieved 3 February 2022.
  25. ↑ Reinhard T (2000). "Lokales Cyclosporin A bei Nummuli nach Keratoconjunctivitis epidemica Eine Pilotstudie - Springer". Der Ophthalmologe. 97 (11): 764–768. doi:10.1007/s003470070025. PMID   11130165. S2CID   399211.
  26. ↑ Paolino A, Alexander H, Broderick C, Flohr C (May 2023). "Non-biologic systemic treatments for atopic dermatitis: Current state of the art and future directions". Clinical and Experimental Allergy. 53 (5): 495–510. doi: 10.1111/cea.14301 . PMID   36949024.
  27. ↑ Dijkmans BA, van Rijthoven AW, Goei Thè HS, Boers M, Cats A (August 1992). "Cyclosporine in rheumatoid arthritis". Seminars in Arthritis and Rheumatism. 22 (1): 30–36. doi:10.1016/0049-0172(92)90046-g. PMID   1411580.
  28. ↑ Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. (June 1994). "Cyclosporine in severe ulcerative colitis refractory to steroid therapy". The New England Journal of Medicine. 330 (26): 1841–5. doi: 10.1056/NEJM199406303302601 . PMID   8196726.
  29. ↑ Naesens M, Kuypers DR, Sarwal M (February 2009). "Calcineurin inhibitor nephrotoxicity" (PDF). Clinical Journal of the American Society of Nephrology. 4 (2): 481–508. doi: 10.2215/CJN.04800908 . PMID   19218475. Archived (PDF) from the original on 20 July 2018. Retrieved 20 April 2018.
  30. ↑ Robert N, Wong GW, Wright JM (January 2010). "Effect of cyclosporine on blood pressure". Cochrane Database of Systematic Reviews (1): CD007893. doi:10.1002/14651858.CD007893.pub2. PMID   20091657.
  31. ↑ Figg WD (February 1990). "Cyclosporine-induced hyperuricemia and gout". The New England Journal of Medicine. 322 (5): 334–336. doi: 10.1056/NEJM199002013220514 . PMID   2296276.
  32. ↑ Agents Classified by the IARC Monographs, Volumes 1–110 Archived 25 October 2011 at the Wayback Machine
  33. ↑ IARC Working Group on the Evaluation of Carcinogenic Risk to Humans (2012). Ciclosporin. International Agency for Research on Cancer. Archived from the original on 28 August 2021. Retrieved 23 February 2018.
  34. ↑ Ganong WF (2005). "27". Review of medical physiology (22nd ed.). New York: McGraw-Hill Medical. p.  530. ISBN   978-0-07-144040-0.
  35. 1 2 3 4 5 6 7 8 9 Mott JL, Zhang D, Freeman JC, Mikolajczak P, Chang SW, Zassenhaus HP (July 2004). "Cardiac disease due to random mitochondrial DNA mutations is prevented by cyclosporin A". Biochemical and Biophysical Research Communications. 319 (4): 1210–5. doi:10.1016/j.bbrc.2004.05.104. PMID   15194495.
  36. 1 2 3 4 5 Youn TJ, Piao H, Kwon JS, Choi SY, Kim HS, Park DG, et al. (December 2002). "Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction". European Journal of Heart Failure. 4 (6): 713–8. doi: 10.1016/S1388-9842(02)00120-4 . PMID   12453541. S2CID   9181082.
  37. ↑ Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW (November 1984). "Cyclophilin: a specific cytosolic binding protein for cyclosporin A". Science. 226 (4674): 544–7. Bibcode:1984Sci...226..544H. doi:10.1126/science.6238408. PMID   6238408.
  38. 1 2 3 4 5 6 Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SA, et al. (October 2010). "Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice". Journal of Clinical Investigation. 120 (10): 3680–7. doi:10.1172/JCI43171. PMC   2947235 . PMID   20890047.
  39. ↑ Briston T, Selwood DL, Szabadkai G, Duchen MR (January 2019). "Mitochondrial Permeability Transition: A Molecular Lesion with Multiple Drug Targets" (PDF). Trends in Pharmacological Sciences. 40 (1): 50–70. doi:10.1016/j.tips.2018.11.004. PMID   30527591. S2CID   54470812. Archived (PDF) from the original on 21 January 2022. Retrieved 2 August 2021.
  40. ↑ Morciano G, Giorgi C, Bonora M, Punzetti S, Pavasini R, Wieckowski MR, et al. (January 2015). "Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury". Journal of Molecular and Cellular Cardiology. 78: 142–53. doi:10.1016/j.yjmcc.2014.08.015. hdl: 11392/2149014 . PMID   25172387.
  41. ↑ Zorov DB, Juhaszova M, Sollott SJ (July 2014). "Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release". Physiological Reviews. 94 (3): 909–50. doi:10.1152/physrev.00026.2013. PMC   4101632 . PMID   24987008.
  42. ↑ Meyrier A (2005). "Treatment of focal segmental glomerulosclerosis". Expert Opinion on Pharmacotherapy. 6 (9): 1539–1549. doi:10.1517/14656566.6.9.1539. PMID   16086641. S2CID   35867347.
  43. ↑ Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. (2008). "The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A". Nature Medicine. 14 (9): 931–938. doi:10.1038/nm.1857. PMC   4109287 . PMID   18724379.
  44. ↑ Borel JF (June 2002). "History of the discovery of cyclosporin and of its early pharmacological development". Wiener Klinische Wochenschrift. 114 (12): 433–7. PMID   12422576.
    Some sources list the fungus under an alternative species name Hypocladium inflatum gams such as Pritchard and Sneader in 2005:
    * Pritchard DI (May 2005). "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". Drug Discovery Today. 10 (10): 688–91. doi:10.1016/S1359-6446(05)03395-7. PMID   15896681.
    * Sneader W (23 June 2005). "Ciclosporin". Drug Discovery — A History . John Wiley & Sons. pp.  298–299. ISBN   978-0-471-89979-2.
    However, the name, "Beauveria nivea", also appears in several other articles including in a 2001 online publication by Harriet Upton entitled "Origin of drugs in current use: the cyclosporin story Archived 2005-03-08 at the Wayback Machine " (retrieved 19 June 2005). Mark Plotkin states in his book Medicine Quest, Penguin Books 2001, pages 46-47, that in 1996 mycology researcher Kathie Hodge found that it is in fact a species of Cordyceps .
  45. ↑ Wang CP, Hartman NR, Venkataramanan R, Jardine I, Lin FT, Knapp JE, et al. (1989). "Isolation of 10 cyclosporine metabolites from human bile". Drug Metabolism and Disposition. 17 (3): 292–6. PMC   3154783 . PMID   2568911.
  46. ↑ Copeland KR, Yatscoff RW, McKenna RM (February 1990). "Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance". Clinical Chemistry. 36 (2): 225–9. doi: 10.1093/clinchem/36.2.225 . PMID   2137384.
  47. ↑ Lawen A (October 2015). "Biosynthesis of cyclosporins and other natural peptidyl prolyl cis/trans isomerase inhibitors". Biochimica et Biophysica Acta (BBA) - General Subjects. 1850 (10): 2111–20. doi:10.1016/j.bbagen.2014.12.009. PMID   25497210.
  48. ↑ Dittmann J, Wenger RM, Kleinkauf H, Lawen A (January 1994). "Mechanism of cyclosporin A biosynthesis. Evidence for synthesis via a single linear undecapeptide precursor". Journal of Biological Chemistry. 269 (4): 2841–6. doi: 10.1016/S0021-9258(17)42019-9 . PMID   8300618.
  49. ↑ Hoppert M, Gentzsch C, Schörgendorfer K (October 2001). "Structure and localization of cyclosporin synthetase, the key enzyme of cyclosporin biosynthesis in Tolypocladium inflatum" (PDF). Archives of Microbiology. 176 (4): 285–93. Bibcode:2001ArMic.176..285H. doi:10.1007/s002030100324. PMID   11685373. S2CID   33075098.[ permanent dead link ]
  50. ↑ Dewick, P. (2001) Medicinal Natural Products. John Wiley & Sons, Ltd. 2nd ed.
  51. ↑ Yang X, Feng P, Yin Y, Bushley K, Spatafora JW, Wang C (October 2018). "Tolypocladium inflatum Benefits Fungal Adaptation to the Environment". mBio. 9 (5). doi:10.1128/mBio.01211-18. PMC   6168864 . PMID   30279281.
  52. ↑ Bushley KE, Raja R, Jaiswal P, Cumbie JS, Nonogaki M, Boyd AE, et al. (June 2013). "The genome of tolypocladium inflatum: evolution, organization, and expression of the cyclosporin biosynthetic gene cluster". PLOS Genetics. 9 (6): e1003496. doi: 10.1371/journal.pgen.1003496 . PMC   3688495 . PMID   23818858.
  53. ↑ Xu L, Li Y, Biggins JB, Bowman BR, Verdine GL, Gloer JB, et al. (March 2018). "Identification of cyclosporin C from Amphichorda felina using a Cryptococcus neoformans differential temperature sensitivity assay". Applied Microbiology and Biotechnology. 102 (5): 2337–2350. doi:10.1007/s00253-018-8792-0. PMC   5942556 . PMID   29396588.
  54. ↑ di Salvo ML, Florio R, Paiardini A, Vivoli M, D'Aguanno S, Contestabile R (January 2013). "Alanine racemase from Tolypocladium inflatum: a key PLP-dependent enzyme in cyclosporin biosynthesis and a model of catalytic promiscuity". Archives of Biochemistry and Biophysics. 529 (2): 55–65. doi:10.1016/j.abb.2012.11.011. PMID   23219598.
  55. 1 2 3 Borel JF, Kis ZL, Beveridge T (1995). "The history of the discovery and development of Cyclosporin (Sandimmune)". In Merluzzi VJ, Adams J (eds.). The search for anti-inflammatory drugs case histories from concept to clinic. Boston: Birkhäuser. pp. 27–63. ISBN   978-1-4615-9846-6. Archived from the original on 5 November 2017.
  56. ↑ Cheng M (2013). "Hartmann Stahelin (1925-2011) and the contested history of cyclosporin A". Clinical Transplantation. 27 (3): 326–329. doi:10.1111/ctr.12072. PMID   23331048. S2CID   39502677.
  57. ↑ Borel JF, Feurer C, Gubler HU, Stähelin H (July 1976). "Biological effects of cyclosporin A: a new antilymphocytic agent". Agents and Actions. 6 (4): 468–75. doi:10.1007/bf01973261. PMID   8969. S2CID   2862779.
  58. ↑ Rüegger A, Kuhn M, Lichti H, Loosli HR, Huguenin R, Quiquerez C, et al. (1976). "[Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity]" [Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity]. Helvetica Chimica Acta (in German). 59 (4): 1075–92. doi:10.1002/hlca.19760590412. PMID   950308.
  59. ↑ Heusler K, Pletscher A (June 2001). "The controversial early history of cyclosporin". Swiss Medical Weekly . 131 (21–22): 299–302. doi: 10.4414/smw.2001.09702 . PMID   11584691. S2CID   24662504.
  60. ↑ Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al. (1978). "Cyclosporin A in patients receiving renal allografts from cadaver donors". The Lancet. 2 (8104–5): 1323–7. doi:10.1016/S0140-6736(78)91970-0. PMID   82836. S2CID   10731038.
  61. ↑ Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GP (July 1981). "Liver transplantation with use of cyclosporin a and prednisone". The New England Journal of Medicine. 305 (5): 266–9. doi:10.1056/NEJM198107303050507. PMC   2772056 . PMID   7017414.
  62. ↑ Kolata G (September 1983). "FDA speeds approval of cyclosporin". Science. 221 (4617): 1273. Bibcode:1983Sci...221.1273K. doi:10.1126/science.221.4617.1273-a. PMID   17776314. On 2 September (1983), the Food and Drug Administration approved cyclosporin, a new drug that suppresses the immune system.
  63. ↑ Gottesman J (20 March 1988). "Milestones in Cardiac Care". Los Angeles Times. Archived from the original on 26 February 2017.
  64. ↑ "First Successful Pediatric Heart Transplant [9 June 1984]". Columbia University Medical Center, Dept. of Surgery, Cardiac Transplant Program. Archived from the original on 1 March 2017. It [cyclosporine] gained FDA approval at the end of 1983, ...
  65. ↑ "Drugs@FDA: FDA Approved Drug Products [Click on "Approval Date(s) and History]". United States Food and Drug Administration. Archived from the original on 1 March 2017. Drug Name(s): Sandimmune (Cyclosporine), Company: Novartis, Action Date: 11/14/1983, Action Type: Approval, Submission Classification: Type 1 - New Molecular Entity, Review Priority: Priority
  66. 1 2 3 Starzl TE (1992). The Puzzle People: Memoirs Of A Transplant Surgeon. University of Pittsburgh Press. doi:10.2307/j.ctt9qh63b. ISBN   978-0-8229-3714-2.
  67. ↑ "Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances". World Health Organization. 1997. To facilitate the translation and pronunciation of INN, "f" should be used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y"; the use of the letters "h" and "k" should be avoided.[ dead link ]
  68. ↑ "The Cyclosporine Story". www.davidmoore.org.uk. January 2013. Archived from the original on 22 October 2022. Retrieved 24 October 2022.
  69. ↑ Gibaud S, Attivi D (August 2012). "Microemulsions for oral administration and their therapeutic applications". Expert Opinion on Drug Delivery. 9 (8): 937–51. doi:10.1517/17425247.2012.694865. PMID   22663249. S2CID   28468973. Archived from the original on 5 March 2018. Retrieved 4 March 2018.
  70. ↑ Min DI (March 1996). "Neoral: a microemulsion cyclosporine". Journal of Transplant Coordination. 6 (1): 5–8. doi:10.7182/prtr.1.6.1.f04016025hh795up (inactive 11 November 2024). PMID   9157923.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
  71. ↑ "Neoral" (PDF). FDA Data Dashboard. Food and Drug Administration (FDA); Novartis. September 2009. Archived (PDF) from the original on 20 October 2022. Retrieved 24 October 2022.
  72. ↑ "Ikervis". Santen. Archived from the original on 3 July 2018. Retrieved 3 July 2018.
  73. ↑ Clinical trial number NCT01287078 for "Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans" at ClinicalTrials.gov.
  74. ↑ Trammer B, Amann A, Haltner-Ukomadu E, Tillmanns S, Keller M, Högger P (November 2008). "Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex vivo". European Journal of Pharmaceutics and Biopharmaceutics. 70 (3): 758–64. doi:10.1016/j.ejpb.2008.07.001. PMID   18656538.
  75. ↑ Administrator. "Hem - NeuroVive Pharmaceutical AB". neurovive.com. Archived from the original on 6 January 2014.
  76. ↑ Ehinger KH, Hansson MJ, Sjövall F, Elmér E (January 2013). "Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor EL" (PDF). Clinical Drug Investigation. 33 (1): 25–34. doi:10.1007/s40261-012-0029-x. PMC   3586182 . PMID   23179472. Archived (PDF) from the original on 26 October 2018. Retrieved 26 October 2018.
  77. ↑ Sullivan PG, Thompson M, Scheff SW (February 2000). "Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury". Experimental Neurology. 161 (2): 631–7. doi:10.1006/exnr.1999.7282. PMID   10686082. S2CID   25190221.
  78. ↑ Uchino H, Elmér E, Uchino K, Lindvall O, Siesjö BK (December 1995). "Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat". Acta Physiologica Scandinavica. 155 (4): 469–71. doi:10.1111/j.1748-1716.1995.tb09999.x. PMID   8719269.
  79. ↑ Sullivan PG, Sebastian AH, Hall ED (February 2011). "Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury". Journal of Neurotrauma. 28 (2): 311–8. doi:10.1089/neu.2010.1646. PMC   3037811 . PMID   21142667.
  80. 1 2 Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ (November 1998). "Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways". Proceedings of the National Academy of Sciences of the United States of America. 95 (23): 13893–8. Bibcode:1998PNAS...9513893M. doi: 10.1073/pnas.95.23.13893 . PMC   24952 . PMID   9811897.
  81. ↑ Wilkinson ST, Johnson DB, Tardif HL, Tome ME, Briehl MM (March 2010). "Increased cytochrome c correlates with poor survival in aggressive lymphoma". Oncology Letters. 1 (2): 227–230. doi:10.3892/ol_00000040. PMC   2927837 . PMID   20798784.
  82. 1 2 Lim HW, De Windt LJ, Mante J, Kimball TR, Witt SA, Sussman MA, et al. (April 2000). "Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition". Journal of Molecular and Cellular Cardiology. 32 (4): 697–709. doi:10.1006/jmcc.2000.1113. PMID   10756124. S2CID   10904494.
  83. 1 2 Archer TM, Boothe DM, Langston VC, Fellman CL, Lunsford KV, Mackin AJ (2014). "Oral cyclosporine treatment in dogs: a review of the literature". Journal of Veterinary Internal Medicine. 28 (1): 1–20. doi:10.1111/jvim.12265. PMC   4895546 . PMID   24341787.
  84. ↑ Palmeiro BS (January 2013). "Cyclosporine in veterinary dermatology". Veterinary Clinics of North America: Small Animal Practice. 43 (1): 153–71. doi:10.1016/j.cvsm.2012.09.007. PMID   23182330.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.